This International Eczema Council consensus statement establishes standardized, globally endorsed definitions for low disease activity (LDA), very low disease activity (vLDA), and remission in atopic dermatitis (AD) using a 3-round modified Delphi process involving international experts. The framework integrates clinician-reported signs (vIGA-AD or EASI) and patient-reported symptoms (PP-NRS) with defined time components, distinguishing between on-drug complete control and off-drug remission. These definitions aim to harmonize clinical trial endpoints, improve cross-study comparability, and support treat-to-target strategies in AD, addressing a longstanding gap in consistent disease activity benchmarks.